Results 91 to 100 of about 18,044 (151)

Recent Advances in Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease: Clinical Relevance and Therapeutic Perspectives. [PDF]

Life (Basel)
Rămoiu-Shehada RI, Mușetescu AE, Florescu LM, Florescu A, Ciurea PL.   +4 more
europepmc   +1 more source

Scleroderma-Specific Autoantibodies and Disease Trajectories in Early Systemic Sclerosis: Insights From a Single-Center Prospective Registry. [PDF]

ACR Open Rheumatol
Jamali M, Kaur A, Huang S, Zahn C, Mulcaire-Jones E, Varga J, Khanna D.   +6 more
europepmc   +1 more source

'It helps me stay on track': patient experiences using a mobile app for self-management of systemic sclerosis with a focus on fatigue in women. [PDF]

Rheumatol Adv Pract
Chen YT, Harper AE, Alore M, Haro E, Morris JT, Khanna D, Murphy SL.   +6 more
europepmc   +1 more source

Pruritus associated with systemic sclerosis: a systematic review of treatment-based clinical trials. [PDF]

Rheumatol Int
Mortezaei K, Pasula R, Nursoy M, Syal A, Panayiotou I, Kumari G, Chatzitoffis A, Milutinovic P, Fadugba OO, Derk CT.   +9 more
europepmc   +1 more source

Unusual presentation of scleroderma: case report. [PDF]

AME Case Rep
Finsterer J.
europepmc   +1 more source

Characterisation of Systemic Sclerosis in a Jordanian Cohort: Clinical Features, Diagnostic Patterns, and Health-Related Quality of Life. [PDF]

Mediterr J Rheumatol
Alnaimat F, Al-Halaseh S, AlSamhori JF, Hanandeh S, Shamaileh J.   +4 more
europepmc   +1 more source

Unlocking multi-institutional insights into disease progression with PEAL as a lossless, one-shot federated learning solution. [PDF]

NPJ Digit Med
Shen Y, Kim JS, Luo C, Zeger SL, Domsic RT, Shah AA, Tong J.   +6 more
europepmc   +1 more source

High levels of vascular cell adhesion molecule-1 associate with a 'vasculopathic' phenotype in systemic sclerosis with higher mortality. [PDF]

Rheumatology (Oxford)
Parker MJS, Nikpour M, Hansen D, Hanson AL, Sahhar J, Brown MA, Corte TJ, Proudman S, Kenna TJ, Australian Scleroderma Interest Group.   +9 more
europepmc   +1 more source

Safety and Microvascular Effect of Four-Year Aminaphtone Administration in Systemic Sclerosis Patients. [PDF]

Open Access Rheumatol
Campitiello R, Sulli A, Hysa E, Pizzorni C, Cutolo M, Paolino S, Gotelli E.   +6 more
europepmc   +1 more source

Predictor factors of successful treatment response in interstitial lung disease-related systemic sclerosis. [PDF]

J Scleroderma Relat Disord
Danasasmita GW, Wibowo SAK, Rumende CM, Rizka A, Sumariyono S, Ariane A, Shatri H, Singh G.   +7 more
europepmc   +1 more source